The Consortium for Clinical Research and Innovation Singapore (CRIS),
a wholly-owned subsidiary of MOH Holdings, was established in 2020 with
the goal of strengthening synergies and developing strategies for national-level
clinical research and translation programmes that are under the stewardship of
the Ministry of Health (MOH).
CRIS brings together the following five entities as business units under a common management and governance structure:
- Singapore Clinical Research Institute (SCRI)
- National Health Innovation Centre Singapore (NHIC)
- Advanced Cell Therapy and Research Institute Singapore (ACTRIS)
- Precision Health Research, Singapore (PRECISE) and
- Singapore Translational Cancer Consortium (STCC)
CRIS aims to make a positive difference to Singapore patients and researchers by ensuring that these clinical research platforms and programmes are at the cutting edge of capability development and innovation through facilitated collaborations and enduring partnerships with research and biomedical entities and communities across the public sector and industry in Singapore.
To nurture and build for Singapore, cutting edge capabilities
and innovation in clinical research and translation.
To ensure unity of mission across research platforms and programmes under the CRIS stable.
To ensure synergies of capabilities, scientific resources, industry development and finances across research platforms and programmes.
To ensure that the platforms and programmes stay relevant and are aligned to the needs of Singapore patients, researchers and industry through constant and regular stakeholder engagement.
To build, review and sustain long term strategies for research platforms and programmes.